Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 1998

View Archived Issues

Connetics: Q4 and FY 1997 highlights

Life Medical Sciences updates shareholders

Inhale Therapeutic Systems: Q4 and FY 1997 highlights

New agents for IBS from Nippon Shinyaku

Novel mitomycin C derivative reported by Sagami

Potent and safe new quinolones from Daiichi

New implant for delivery of LHRH agonists

Novel compound MK6059 isolated by Meiji Seika/Mitsubishi Chemical

Wyeth-Ayerst describes synthesis and pharmacological profile of new agent for stroke

PLA2 inhibitors --BM-16.2115, mepacrine and manoalide-- reduce human leukocyte chemotaxis

Institute of Microbial Chemistry discovers new antibacterial/cytotoxic antibiotic

SGLT inhibitors under evaluation at Tanabe as antidiabetic agents

Antibradycardic M2 receptor antagonists prepared at Yamanouchi

Warning issued for Duract related to potential hepatotoxicity

Safety warnings issued by FDA for Hismanal

Idec evaluates humanized anti-gp39 antibody in phase I

GeneMedicine and Corange progress in cancer alliance

Lilly describes second-generation NK1 antagonist

New antiinflammatory agents prepared by Brazilian academics

Vorozole safe and effective in phase II EORTC study

Preclinical profile of S-4661, a new carbapenem, characterized

Macritonin clinical trial update

Topoisomerase I inhibitor tested in phase I trial

Two combinations compared for treatment of multidrug-resistant falciparum malaria

Targeted Genetics to report tgDCC-E1A clinical data

Anti-Candida activity of voriconazole compared to other antifungal agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...